![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rani Therapeutics Holdings Inc | NASDAQ:RANI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.29 | -8.61% | 3.08 | 1.55 | 4.30 | 3.84 | 3.01 | 3.30 | 209,398 | 05:00:05 |
The details of the presentation are as follows:
Abstract Title: Daily Administration of An Oral Robotic Pill (RT-102) Safely and Reliably Delivers Teriparatide with High Bioavailability in Women Volunteers: A Phase I Study Presentation Number: SAT-435 Presentation Type: Poster PresentationSession: Poster Session IDate & Time: Saturday, October 14, 2023, 1:30pm-3:00pm PTLocation: Vancouver Convention CentrePresenter: Arvinder Dhalla, PhD
Information about ASBMR 2023 may be accessed at https://www.asbmr.org/annual-meeting.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit www.ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
1 Year Rani Therapeutics Chart |
1 Month Rani Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions